Failsafe program escape and EMT: A deleterious partnership

Seminars in Cancer Biology

Volumn 21, Issue 6, 2011, Pages 392-396

  Ansieau, Stéphane ^a,b   Courtois Cox, Stéphanie ^a,b   Morel, Anne Pierre ^a,b,c   Puisieux, Alain ^a,b,c,d  

^a CENTRE DE RECHERCHE EN CANCÉROLOGIE DE LYON   (France)

^b UNIVERSITÉ DE LYON   (France)

^c CENTRE LÉON BÉRARD   (France)

^d INSTITUT UNIVERSITAIRE DE FRANCE   (France)

Author keywords

EMT; Failsafe program escape; Tumor initiation

Indexed keywords

PROTEIN P53; TRANSCRIPTION FACTOR TWIST; TRANSCRIPTION FACTOR TWIST1; UNCLASSIFIED DRUG;

APOPTOSIS; CANCER GROWTH; CANCER STEM CELL; CELL DIFFERENTIATION; CELL MIGRATION; CELL PROLIFERATION; CELL SURVIVAL; CELLULAR STRESS RESPONSE; CYTOSKELETON; EPITHELIAL MESENCHYMAL TRANSITION; EPITHELIUM CELL; HUMAN; PROTEIN DEPLETION; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; PROTEIN TARGETING; REVIEW; SENESCENCE;

DISEASE PROGRESSION; EPITHELIAL-MESENCHYMAL TRANSITION; HUMANS; NEOPLASMS; TUMOR ESCAPE;

EID: 82755177911     PISSN: 1044579X     EISSN: 10963650     Source Type: Journal    
DOI: 10.1016/j.semcancer.2011.09.014     Document Type: Review

References (59)

1. Bartkova J., Horejsi Z., Koed K., Kramer A., Tort F., Zieger K., et al. DNA damage response as a candidate anti-cancer barrier in early human tumorigenesis. Nature 2005, 434:864-870.
2. Braig M., Lee S., Loddenkemper C., Rudolph C., Peters A.H., Schlegelberger B., et al. Oncogene-induced senescence as an initial barrier in lymphoma development. Nature 2005, 436:660-665.
3. Collado M., Gil J., Efeyan A., Guerra C., Schuhmacher A.J., Barradas M., et al. Tumour biology: senescence in premalignant tumours. Nature 2005, 436:642.
4. Chen Z., Trotman L.C., Shaffer D., Lin H.-K., Dotan Z.A., Niki M., et al. Crucial role of p53-dependent cellular senescence in suppression of Pten-deficient tumorigenesis. Nature 2005, 436:725-730.
5. Gorgoulis V.G., Vassiliou L.V., Karakaidos P., Zacharatos P., Kotsinas A., Liloglou T., et al. Activation of the DNA damage checkpoint and genomic instability in human precancerous lesions. Nature 2005, 434:907-913.
6. Bartkova J., Rezaei N., Liontos M., Karakaidos P., Kletsas D., Issaeva N., et al. Oncogene-induced senescence is part of the tumorigenesis barrier imposed by DNA damage checkpoints. Nature 2006, 444:633-637.
7. Peinado H., Olmeda D., Cano A. Snail, Zeb and bHLH factors in tumour progression: an alliance against the epithelial phenotype?. Nat Rev Cancer 2007, 7:415-428.
8. Thiery J.P., Acloque H., Huang R.Y., Nieto M.A. Epithelial-mesenchymal transitions in development and disease. Cell 2009, 139:871-890.
9. Tribulo C., Aybar M.J., Sanchez S.S., Mayor R. A balance between the anti-apoptotic activity of Slug and the apoptotic activity of msx1 is required for the proper development of the neural crest. Dev Biol 2004, 275:325-342.
10. Vega S., Morales A.V., Ocana O.H., Valdes F., Fabregat I., Nieto M.A. Snail blocks the cell cycle and confers resistance to cell death. Genes Dev 2004, 8:1131-1143.
11. Wu W.S., Heinrichs S., Xu D., Garrison S.P., Zambetti G.P., Adams J.M., et al. Slug antagonizes p53-mediated apoptosis of hematopoietic progenitors by repressing puma. Cell 2005, 123:641-653.
12. Rodriguez-Aznar E., Nieto M.A. Repression of Puma by Scratch2 is required for neuronal survival during embryonic development. Cell Death Differ 2011, 18:1196-1207.
13. Ansieau S., Morel A.-P., Hinkal G., Bastid J., Puisieux A. TWISTing an embryonic transcription factor into an oncoprotein. Oncogene 2010, 29:3173-3184.
14. Yang J., Mani S.A., Donaher J.L., Ramaswamy S., Itzykson R.A., Come C., et al. Twist, a master regulator of morphogenesis, plays an essential role in tumor metastasis. Cell 2004, 117:927-939.
15. Trimboli A.J., Fukino K., de Bruin A., Wei G., Shen L., Tanner S.M., et al. Direct evidence for epithelial-mesenchymal transitions in breast cancer. Cancer Res 2008, 68:937-945.
16. Brabletz T., Jung A., Hermann K., Gunther K., Hohenberger W., Kirchner T. Nuclear overexpression of the oncoprotein beta-catenin in colorectal cancer is localized predominantly at the invasion front. Pathol Res Pract 1998, 194:701-704.
17. Mani S.A., Guo W., Liao M.J., Eaton E.N., Ayyanan A., Zhou A.Y., et al. The epithelial-mesenchymal transition generates cells with properties of stem cells. Cell 2008, 133:704-715.
18. Morel A.-P., Lievre M., Thomas C., Hinkal G., Ansieau S., Puisieux A. Generation of breast cancer stem cells through epithelial-mesenchymal transition. PLoS One 2008, 3:e2888.
19. Vesuna F., Lisok A., Kimble B., Raman V. Twist modulates breast cancer stem cells by transcriptional regulation of CD24 expression. Neoplasia 2009, 11:1318-1328.
20. Gupta P.B., Chaffer C.L., Weinberg R.A. Cancer stem cells: mirage or reality?. Nat Med 2009, 15:1010-1012.
21. Ansieau S., Morel A.-P., Puisieux A. From where do cancer-initiating cells originate?. Cancer Stem Cells Theories and Practice (InTech) 2011, 34-46.
22. Maestro R., Dei Tos A.P., Hamamori Y., Krasnokutsky S., Sartorelli V., Kedes L., et al. Twist is a potential oncogene that inhibits apoptosis. Genes Dev 1999, 13:2207-2217.
23. Valsesia-Wittmann S., Magdeleine M., Dupasquier S., Garin E., Jallas A.-C., Combaret V., et al. Oncogenic cooperation between H-Twist and N-Myc overrides failsafe programs in cancer cells. Cancer Cell 2004, 6:625-630.
24. Lee S.H., Lee S.J., Jung Y.S., Xu Y., Kang H.S., Ha N.C., et al. Blocking of p53-Snail binding, promoted by oncogenic K-Ras, recovers p53 expression and function. Neoplasia 2009, 11:22-31.
25. Sayan A.E., Griffiths T.R., Pal R., Browne G.J., Ruddick A., Yagci T., et al. SIP1 protein protects cells from DNA damage-induced apoptosis and has independent prognostic value in bladder cancer. Proc Natl Acad Sci USA 2009, 106:14884-14889.
26. Perez-Caro M., Bermejo-Rodriguez C., Gonzalez-Herrero I., Sanchez-Beato M., Piris M.A., Sanchez-Garcia I. Transcriptomal profiling of the cellular response to DNA damage mediated by Slug (Snai2). Br J Cancer 2008, 98:480-488.
27. Ansieau S., Bastid J., Doreau A., Morel A.-P., Bouchet B.P., Thomas C., et al. Induction of EMT by twist proteins as a collateral effect of tumor-promoting inactivation of premature senescence. Cancer Cell 2008, 14:79-89.
28. Ohashi S., Natsuizaka M., Wong G.S., Michaylira C.Z., Grugan K.D., Stairs D.B., et al. Epidermal growth factor receptor and mutant p53 expand an esophageal cellular subpopulation capable of epithelial-to-mesenchymal transition through ZEB transcription factors. Cancer Res 2010, 70:4174-4184.
29. Liu Y., El-Naggar S., Darling D.S., Higashi Y., Dean D.C. Zeb1 links epithelial-mesenchymal transition and cellular senescence. Development 2008, 135:579-588.
30. Lee K.E., Bar-Sagi D. Oncogenic KRas suppresses inflammation-associated senescence of pancreatic ductal cells. Cancer Cell 2010, 18:448-458.
31. Felsher D.W. Oncogene addiction versus oncogene amnesia: perhaps more than just a bad habit?. Cancer Res 2008, 68:3081-3086.
32. Wang Y., Ngo V.N., Marani M., Yang Y., Wright G., Staudt L.M., et al. Critical role for transcriptional repressor Snail2 in transformation by oncogenic RAS in colorectal carcinoma cells. Oncogene 2010, 29:4658-4670.
33. Arima Y., Inoue Y., Shibata T., Hayashi H., Nagano O., Saya H., et al. Rb depletion results in deregulation of E-cadherin and induction of cellular phenotypic changes that are characteristic of the epithelial-to-mesenchymal transition. Cancer Res 2008, 68:5104-5112.
34. Liu Y., Clem B., Zuba-Surma E.K., El-Naggar S., Telang S., Jenson A.B., et al. Mouse fibroblasts lacking RB1 function form spheres and undergo reprogramming to a cancer stem cell phenotype. Cell Stem Cell 2009, 4:336-347.
35. Liu Y., Dean D.C. Tumor initiation via loss of cell contact inhibition versus Ras mutation: do all roads lead to EMT?. Cell Cycle 2010, 9:897-900.
36. Wellner U., Schubert J., Burk U.C., Schmalhofer O., Zhu F., Sonntag A., et al. The EMT-activator ZEB1 promotes tumorigenicity by repressing stemness-inhibiting microRNAs. Nat Cell Biol 2009, 11:1487-1495.
37. Chang C.J., Chao C.H., Xia W., Yang J.Y., Xiong Y., Li C.W., et al. p53 regulates epithelial-mesenchymal transition and stem cell properties through modulating miRNAs. Nat Cell Biol 2011, 13:317-323.
38. Elenbaas B., Spirio L., Koerner F., Fleming M.D., Zimonjic D.B., Donaher J.L., et al. Human breast cancer cells generated by oncogenic transformation of primary mammary epithelial cells. Genes Dev 2001, 15:50-65.
39. Kogan-Sakin I., Tabach Y., Buganim Y., Molchadsky A., Solomon H., Madar S., et al. Mutant p53(R175H) upregulates Twist1 expression and promotes epithelial-mesenchymal transition in immortalized prostate cells. Cell Death Differ 2011, 18:271-281.
40. Wang S.P., Wang W.L., Chang Y.L., Wu C.T., Chao Y.C., Kao S.H., et al. p53 controls cancer cell invasion by inducing the MDM2-mediated degradation of Slug. Nat Cell Biol 2009, 11:694-704.
41. Blick T., Hugo H., Widodo E., Waltham M., Pinto C., Mani S.A., et al. Epithelial mesenchymal transition traits in human breast cancer cell lines parallel the CD44(hi/)CD24 (lo/-) stem cell phenotype in human breast cancer. J Mammary Gland Biol Neoplasia 2010, 15:235-252.
42. Bearss D.J., Lee R.J., Troyer D.A., Pestell R.G., Windle J.J. Differential effects of p21(WAF1/CIP1) deficiency on MMTV-ras and MMTV-myc mammary tumor properties. Cancer Res 2002, 62:2077-2084.
43. Liu M., Casimiro M.C., Wang C., Shirley L.A., Jiao X., Katiyar S., et al. p21CIP1 attenuates Ras- and c-Myc-dependent breast tumor epithelial mesenchymal transition and cancer stem cell-like gene expression in vivo. Proc Natl Acad Sci USA 2009, 106:19035-19039.
44. Libusova L., Stemmler M.P., Hierholzer A., Schwarz H., Kemler R. N-cadherin can structurally substitute for E-cadherin during intestinal development but leads to polyp formation. Development 2010, 137:2297-2305.
45. Yang M.H., Hsu D.S., Wang H.W., Wang H.J., Lan H.Y., Yang W.H., et al. Bmi1 is essential in Twist1-induced epithelial-mesenchymal transition. Nat Cell Biol 2010, 12:982-992.
46. Onder T.T., Gupta P.B., Mani S.A., Yang J., Lander E.S., Weinberg R.A. Loss of E-cadherin promotes metastasis via multiple downstream transcriptional pathways. Cancer Res 2008, 68:3645-3654.
47. Derksen P.W., Braumuller T.M., van der Burg E., Hornsveld M., Mesman E., Wesseling J., et al. Mammary-specific inactivation of E-cadherin and p53 impairs functional gland development and leads to pleomorphic invasive lobular carcinoma in mice. Dis Model Mech 2011, 4:347-358.
48. Kwok W.K., Ling M.T., Yuen H.F., Wong Y.C., Wang X. Role of p14ARF in TWIST-mediated senescence in prostate epithelial cells. Carcinogenesis 2007, 28:2467-2475.
49. Husemann Y., Geigl J.B., Schubert F., Musiani P., Meyer M., Burghart E., et al. Systemic spread is an early step in breast cancer. Cancer Cell 2008, 13:58-68.
50. Kwok W.K., Ling M.T., Lee T.W., Lau T.C., Zhou C., Zhang X., et al. Up-regulation of TWIST in prostate cancer and its implication as a therapeutic target. Cancer Res 2005, 65:5153-5162.
51. Ohuchida K., Mizumoto K., Ohhashi S., Yamaguchi H., Konomi H., Nagai E., et al. Twist, a novel oncogene, is upregulated in pancreatic cancer: clinical implication of Twist expression in pancreatic juice. Int J Cancer 2007, 120:1634-1640.
52. Zhang Z., Xie D., Li X., Wong Y.C., Xin D., Guan X.Y., et al. Significance of TWIST expression and its association with E-cadherin in bladder cancer. Hum Pathol 2007, 38:598-606.
53. Singh A., Greninger P., Rhodes D., Koopman L., Violette S., Bardeesy N., et al. A gene expression signature associated with "K-Ras addiction" reveals regulators of EMT and tumor cell survival. Cancer Cell 2009, 15:489-500.
54. Hong H., Takahashi K., Ichisaka T., Aoi T., Kanagawa O., Nakagawa M., et al. Suppression of induced pluripotent stem cell generation by the p53-p21 pathway. Nature 2009, 460:1132-1135.
55. Kawamura T., Suzuki J., Wang Y.V., Menendez S., Morera L.B., Raya A., et al. Linking the p53 tumour suppressor pathway to somatic cell reprogramming. Nature 2009, 460:1140-1144.
56. Li H., Collado M., Villasante A., Strati K., Ortega S., Canamero M., et al. The Ink4/Arf locus is a barrier for iPS cell reprogramming. Nature 2009, 460:1136-1139.
57. Utikal J., Polo J.M., Stadtfeld M., Maherali N., Kulalert W., Walsh R.M., et al. Immortalization eliminates a roadblock during cellular reprogramming into iPS cells. Nature 2009, 460:1145-1148.
58. Schickel R., Park S.M., Murmann A.E., Peter M.E. miR-200c regulates induction of apoptosis through CD95 by targeting FAP-1. Mol Cell 2010, 38:908-915.
59. Brabletz S., Bajdak K., Meidhof S., Burk U., Niedermann G., Firat E., et al. The ZEB1/miR-200 feedback loop controls Notch signalling in cancer cells. EMBO J 2011, 30:770-782.